NSCMID Exchange Programme

The NSCMID exchange programme is only available to NSCMID members - both the person that seeks to go on exchange and the contact person from the department that accepts the visitor should be members of NSCMID.

Members can apply for grants to cover transportation and accommodation costs. It is not possible to apply for reimbursement of wages. Each applicant can apply for a maximum of 25.000 SEK.

The NSCMID exchange-programme aims to foster collaborations in research or the exchange of clinical or laboratory expertise. Both the applicant and the department he/she wishes to visit should be able to gain from the visit.

NSCMID will mainly support exchange between the Nordic countries, but exceptions can be made.

The recipient of an exchange grant is obliged to deliver a written report on the stay within 6 months of the stay.

Applications are handled by the NSCMID board on a running schedule as they are received. Applications should include a short description of the planned stay and a budget.

Applications may be sent to Annette.strandbo@clin.au.dk

SSAC foundation research grants

The Scandinavian Society for Antimicrobial Chemotherapy Foundation distributes grants for research related to the treatment of infectious diseases with antibacterial, antiviral, antimycotical or antiparasitical agents.

The financial assets of the Foundation originate from the earnings of the 18th International Congress of Chemotherapy in Stockholm in 1993. The assets are managed by the Swedish Society of Medicine (Svenska Läkaresällskapet) and distribution of grants are decided on by the SSAC Foundation Board.

SSAC Foundation grants can be applied for by NSCMID members only.

The application period starts 1 December 2019.

Read more and apply here.

In 2018 the SSAC foundation gave out a total of 905.000 SEK to 16 recipients. Find the list of recipients here

In 2017 the SSAC foundation gave out a total of 995.000 SEK to 14 recipients. Find the list of recipients here

SSAC-grant recipients 2019

The SSAC Foundation received 14 eligible applications in 2019. After the reviewing process, 10 applicants were granted support - Congratulations!

 

Applicant Title Granted amount (SEK)
Bergman, Peter Boosting Innate Immunity in the Lung to Fight Multidrug Resistant Bacteria 100000
Matussek, Andreas A Nordic multi-center study of hemolytic uremic syndrome causing Shiga toxin producing Escherichia coli 100000
Bjarnason, Agnar Community acquired pneumonia - Etiology and diagnostics 100000
Blenstrup Patsche, Cecilie Treatment of tuberculosis with nutritional supplements - a randomized trial to improve treatment outcome of patients with tuberculosis (NUTRIATO) 50000
Hughes, Diarmaid Antibiotic Resistance Evolution in Bacterial Biofilms:
The Interplay of Selection, Mutation Rate, and Horizontal Genetic Transfer.
50000
Nilsson, Anna People who inject drugs; Longitudinal Staphylococcus aureus colonization pattern and the impact on the infection frequency by regular showers with chlorhexidine. 50000
Wejse, Christian Clinical scoring tool for point-of-care diagnosis of tuberculosis - ClinPOC-TB 50000
Aro, Tuomas Resistant bacteria and stool microbes among migrants and refugees 40000
Hilmarsdottir, Ingibjorg Mycoplasma genitalium in Iceland: first study on prevalence in STI clinic attendees, and evaluation of nucleic acid amplification tests for detection of M. genitalium and antibiotic resistance markers 40000
Lennerstrand, Johan Identification of inhibitors against protease of Zika, TBE and other flaviviruses 40000

Reports from grant recipients 2016

Bergman Peter. Title: “Host Directed Therapy against Antimicrobial Resistant Bacteria”. Decision sum: 60 000
Summary NSCMID: We develop the concept of Host Directed Therapy, based on induction of antimicrobial peptides, and apply this principle to treat multidrug resistant bacteria.
Diarienr: 591671

Damsgaard Gunst, Jesper. Title: “The Nordic HIV-1 Latency and Cure Research Collaboration (nCURE) cohort.”. Decision sum: 65 000
Summary NSCMID: The Nordic HIV-1 Latency and Cure Research Collaboration (nCURE) cohort database has been established. Included in the nCURE cohort are individuals on ART with viral suppression for ≥18 months (one blip every two years is OK) and current CD4+ T cell counts >500 cells/μL. Hopefully the nCURE cohort will form basis for identifying HIV-1 infected patients suitable for participation in future clinical cure-related trials across the Nordic countries.
The procedure leukapheresis has been established to be used in HIV-1 infected individuals. Leukapheresis is a procedure to collect large amounts of white blood cells from the body. Leukapheresis uses a machine to separate out the different types of cells that are in the blood, removes some of the leukocytes including the peripheral blood mononuclear cells (PBMCs), and returns the other components of the blood back into the body.
The nCURE cohort has received funding from the Scandinavian Society for Antimicrobial Chemotherapy Foundation.
Diarienr: 592591

Hasman, Henrik. Title: “Characterization of carbapenemase-encoding plasmids implicated in multispecies outbreaks and interspecies spread in single patients using whole genome sequence data obtained from Nanopore MinION and Illumina MiSeq.”. Decision sum: 50 000
Summary NSCMID: This project aimed to gain knowledge and experience on assembling and comparing plasmid sequences from carbapenemase producing bacteria by using the newest sequencing technologies (combining Illumina MiSeq and Oxford Nanopore Technologies MinION sequencing). The main conclusion was that this methodological approach was to some extend feasible when combined with manually curation of plasmid sequences, but a fully automated process could not be established.
Diarienr: 588921

Hughes, Diarmaid. Title: “Interplay in the Selection of Efflux Regulatory Mutations in the Evolution of Antibiotic Resistant Bacterial Pathogens”. Decision sum: 50 000
Summary NSCMID: In the study we asked whether the spectrum of mutations in marR in ciprofloxacin-resistant clinical isolates of Escherichia coli showed evidence of selection bias, either to reduce fitness costs, or to increase drug resistance. The significant finding from this SSAC-supported study is that mutations in marR selected in ciprofloxacin-resistant clinical isolates are strongly biased against inactivating mutations. Selection favours mutant alleles that have the lowest fitness costs, even though these cause only modest reductions in drug susceptibility. This suggests that selection for high relative fitness ismore important than selection for increased resistance in determining which alleles of marR will be selected in resistant clinical isolates.
Praski Alzrigat, L., Huseby, D.L., Brandis, G. and Hughes, D. (2017) 'Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli. J. Antimicrob. Chemother. 72, 3016-3024.
Diarienr: 590481

Inghammar, Malin Title: “Serious liver side-effects of macrolide and fluoroquinolone antibiotics”. Decision sum: 60 000
Summary NSCMID: The manuscript is being finalized for submission within a few weeks. We are a bit reluctant to publish any details of the results before the manuscript is accepted for publication due to copyright issues.
Diarienr: 591701

Lennerstrand, Johan. Title: “Study of resistance in Hepatitis C virus prior to treatment with new directly acting antivirals. A Nordic Multicenter Study”. Decision sum: 60 000
Summary NSCMID: Study of resistance in Hepatitis C virus prior to treatment with new directly acting antivirals. A Nordic Multicenter Study.
Diarienr: 594761

Vibholm, Line. Title: ” Toll-like receptor 9 enhancement of antiviral immunity in chronic HIV-1 infection: a phase 1b/2a trial: TEACH – trial 2.0”. Decision sum: 50 000
Summary NSCMID: The purpose of the study was to evaluate safety and antiviral immune response of 24 weeks administration of the TLR9 agonist Lefitolimod in HIV infected individuals. We hypothesized, that Lefitolimod augments HIV-specific CD8+ T cell cytotoxic activity and reactivates latent proviruses. This enhanced activity leads to killing of HIV-expressing cells, reducing the latent HIV-1 reservoir and increasing time to rebound.
We enrolled 14 HIV infected, cART treated individuals in a phase Ib/IIa, open label, clinical trial.
Lefitolimod was safe and well tolerated. After 24 weeks treatment, cART was withdrawn for an analytical treatment interruption. One individual, who initiated cART during chronic infection, suppressed plasma HIV RNA levels below limits of detection (20 c/mL) for 136 days. This individual did not resemble previous reports on spontaneous controllers (key characteristics of "ID 113": years of unsuccessful ART, pre-cART HIV RNA >100,000 c/mL, nadir CD4 of 29 cells/μL). Time to rebound for the remaining individuals participating in the ATI was comparable to historical data.
Immunological analyses revealed; proportions of HLA-DR/CD38+ Effector Memory (TEM) and Terminally Differentiated (TTD) CD8+ T cells increased after 12 and 24 weeks. Intracellular cytokine stain, showed a significant (p=0.0068) cohort-wide increase in IFN-γ response in HIV-specific CD8+ T Effector Memory (TEM) cells from baseline to after 24 weeks treatment. "ID 113" had the highest percentage of polyfunctional HIV-specific CD8+ TEM (double positive IFN-γ+/TNF-α+ and triple positive IL-2+/IFN-γ+/TNF-α+) which further increased 3-fold from baseline to end of treatment, indicating that polyfunctional HIV-specific CD8+ T cells might have contributed to the observed virological control.
In conclusion: Lefitolimod was safe, enhanced HIV-specific CD8+ TEM cell responses, allowed us to observe increased time to rebound in an individual with strong polyfunctional HIV-specific CD8+ TEM responses.
Diarienr: 593951